Generic Name

TiZANidine

Brand Names
Ontralfy, Tizandine, Tizanidne, Zanaflex
FDA approval date: July 03, 2002
Classification: Central alpha-2 Adrenergic Agonist
Form: Tablet, Capsule, Solution

What is Ontralfy (TiZANidine)?

Ontralfy is indicated for the treatment of spasticity in adults. Ontralfy is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity in adults.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures

Objective: To measure postoperative pain control in patients in two treatment arms of ORIF of the clavicle: a treatment group given a nonopioid pain control regimen, and a standard of care control group given standard opioid pain control regimen. Study

Effect of Neural Constraints on Movement in Stroke

Summary: This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in moveme...

Postoperative Tizanidine Use in Pelvic Reconstructive Surgery: A Pilot Study

Summary: The goal of this clinical trial is to evaluate whether adding tizanidine to the standard postoperative pain regimen improves recovery after pelvic reconstructive surgery in adult women. The main questions it aims to answer are: Does postoperative tizanidine improve patient-reported recovery 4-6 weeks after surgery? Does tizanidine reduce postoperative pain, opioid use, constipation, and healthcare...

Brand Information